Featured
-
-
Article
| Open Access
Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions
- M. Medrano
- , M. Contreras
- & J. A. Pérez-Simón
-
Perspective
| Open Access
Redefining cancer research for therapeutic breakthroughs
- Arseniy E. Yuzhalin
-
Article
| Open Access
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer
- Cath Eberlein
- , Stuart C. Williamson
- & Simon T. Barry
-
Article
| Open Access
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method
- S. R. Javed
- , S. Lord
- & M. A. Hawkins
-
Perspective
| Open AccessAspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
- Peter Elwood
- , Gareth Morgan
- & Marcus Longley
-
Article |
The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma
- Zhijian Kuang
- , Kaiqiang Guo
- & Meijuan Fang
-
Comment
| Open Access
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities
In light of the disappointing termination of clinical trials with potent complex I inhibitors, such as IACS-010759, justification for oxidative phosphorylation inhibitors and mitochondrial targeting strategies has been called into question. Consideration of these agents’ potency, tissue selectivity and toxicity demonstrate what lessons can be learned from this failure and where new opportunities lie.
- Nicole D. Machado
- , Lisa C. Heather
- & Geoff S. Higgins
-
Review Article |
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies
- Austin Wesevich
- , Daniel A. Goldstein
- & Mark J. Ratain
-
Review Article
| Open Access
PARP inhibitors: enhancing efficacy through rational combinations
- Deepak Bhamidipati
- , Jaime I. Haro-Silerio
- & Natalie Ngoi
-
Article
| Open Access
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
- Helena J. Janse van Rensburg
- , Zhihui Liu
- & Aaron R. Hansen
-
Article
| Open Access
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
- Rebecca Kristeleit
- , Ruth Plummer
- & Udai Banerji
-
Review Article |
The emerging role of PI3K inhibitors for solid tumour treatment and beyond
- Carmen Belli
- , Matteo Repetto
- & Giuseppe Curigliano
-
Article
| Open Access
Azithromycin, a potent autophagy inhibitor for cancer therapy, perturbs cytoskeletal protein dynamics
- Naoharu Takano
- , Masaki Hiramoto
- & Keisuke Miyazawa
-
Perspective
| Open AccessIs it still worth pursuing the repurposing of metformin as a cancer therapeutic?
- Simon R. Lord
- & Adrian L. Harris
-
Article
| Open Access
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials
- Jerold Loh
- , Jiaxuan Wu
- & Cheng E. Chee
-
Review Article
| Open Access
Head and neck cancer patient-derived tumouroid cultures: opportunities and challenges
- B. W. M. Thilini J. Basnayake
- , Paul Leo
- & Chamindie Punyadeera
-
Article
| Open Access
Norepinephrine inhibits CD8+ T-cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma
- Qishun Geng
- , Lifeng Li
- & Jie Zhao
-
Article |
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies
- Oana C. Danciu
- , Matthias Holdhoff
- & Arkadiusz Z. Dudek
-
Comment
| Open AccessAdditional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
- Sarah P. Blagden
- , Ly-Mee Yu
- & Louise C. Brown
-
Article |
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
- Giuseppe Curigliano
- , Geoffrey I. Shapiro
- & Zev A. Wainberg
-
Article |
Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE
- Geoffrey A. Watson
- , Zachary W. Veitch
- & Aaron R. Hansen
-
Review Article |
Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity
- Zhangchi Dongye
- , Jian Li
- & Yuzhang Wu
-
Article |
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer
- Mark K. Doherty
- , Vincent C. Tam
- & Jennifer J. Knox
-
Article
| Open Access
Autoregulation of H+/lactate efflux prevents monocarboxylate transport (MCT) inhibitors from reducing glycolytic lactic acid production
- Wiktoria Blaszczak
- , Hannah Williams
- & Pawel Swietach
-
Article |
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
- Sukeshi Patel Arora
- , Laura Tenner
- & Devalingam Mahalingam
-
Article
| Open Access
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours
- Aya El Helali
- , Ruth Plummer
- & Richard H. Wilson
-
Review Article
| Open Access
POH1/Rpn11/PSMD14: a journey from basic research in fission yeast to a prognostic marker and a druggable target in cancer cells
- Vito Spataro
- & Antoine Buetti-Dinh
-
Article
| Open Access
Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic
- Ulrike Tontsch-Grunt
- , Paula-Elena Traexler
- & Flavio Solca
-
Perspective
| Open Access
Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours
- Nicola J. Farrer
- , Geoff S. Higgins
- & Ian H. Kunkler
-
Article
| Open Access
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
- Carolyn J. Edwards
- , Angelica Sette
- & Andrew J. Pierce
-
Article |
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours
- Debbie Robbrecht
- , Christiane Jungels
- & Ahmad Awada
-
Article |
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine
- Vincent Chen
- , Shigeki Umemura
- & Giuseppe Giaccone
-
Article
| Open Access
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
- Cristina Gasparetto
- , Gary J. Schiller
- & Brea Lipe
-
Article
| Open Access
Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
- Jason D. Lickliter
- , Mark Voskoboynik
- & Michael Millward
-
Article
| Open Access
Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing
- Yao Jiang
- , Andrew D. Southam
- & Farhat L. Khanim
-
Article
| Open Access
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
- Robin Kate Kelley
- , Rebecca Miksad
- & Ghassan K. Abou-Alfa
-
Perspective
| Open Access
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group
- Thibaud Koessler
- , Maria Alsina
- & Markus Moehler
-
Review Article
| Open AccessAn urgent call to raise the bar in oncology
- John-John B. Schnog
- , Michael J. Samson
- & Ashley J. Duits
-
Review Article |
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
- Rafael Rosell
- , Andrés Felipe Cardona
- & Mariacarmela Santarpia
-
Article
| Open Access
Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies
- Sebastian Bauer
- , George D. Demetri
- & Philippe A. Cassier
-
Perspective
| Open AccessMolecularly profiled trials: toward a framework of actions for the “nil actionables”
- Allan Michael Jordan
-
Article |
Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents
- Xing Xu
- , Yao Wang
- & Peter W. Gunning
-
Comment
| Open Access
Searching for treatments for non-G12C-KRAS mutant cancers
- Christina Guo
- & Udai Banerji
-
Perspective
| Open Access
Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework
- Kamal S. Saini
- & Chris Twelves
-
-
Article
| Open Access
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma
- Chris Twelves
- , Michael Sabel
- & Jens Panse
-
Article
| Open Access
Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial
- Arinilda Campos Bragagnoli
- , Raphael L. C. Araujo
- & João Paulo da Silveira Nogueira Lima
-
Editorial
| Open Access
Correlation of anti-tumour drug resistance with epigenetic regulation
- Takuma Hayashi
- & Ikuo Konishi
-
Article
| Open Access
A novel cancer preventative botanical mixture, TriCurin, inhibits viral transcripts and the growth of W12 cervical cells harbouring extrachromosomal or integrated HPV16 DNA
- Linda Saxe Einbond
- , Jing Zhou
- & Mario R. Castellanos
Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study
Targeting acetate metabolism: Achilles’ nightmare